The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Sosei Heptares and Neurocrine hope to be able to achieve the benefits of muscarinic agonists without the toxicity, in a single molecule. "Our selective muscarinic agonist approach is supported by ...